Cota Brings on Innovative Veteran CEO to Drive Next Phase of Growth and Delivery of Breakthrough Technology and Insights

Michael Doyle to join oncology healthcare technology leader

News provided by

Oct 30, 2018, 09:06 ET

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Cota, Inc., a real-world data and analytics company, announces that Michael Doyle joins the organization as president and chief executive officer (CEO), effective today. He will also serve as a member of Cota's board of directors. Doyle joins Cota from QPID Health, where he served as president and chief executive officer from 2012 to 2018.

"As we continue to scale and deliver on the promise of our technology, the addition of Mike Doyle to lead our team is a significant win for our partners, customers, and oncology patients," said Andrew Pecora M.D., founder and executive chairman of Cota. "I'm so proud that he has chosen to join us at this important stage of our growth. He has spent most of the past three decades as a chief executive officer – much of that time in organizations that also operate at the intersection of healthcare analytics and solutions designed to improve insights and patient outcomes, while reducing the cost of care."

Doyle has a lengthy track record providing vision, leadership, innovation and team-building to successfully create business value in investor-backed, rapid-growth, public and private healthcare and technology companies. In December 2012, he and his team acquired QPID Health from Partners Health Care and Massachusetts General Hospital, and established it as a commercial healthcare software technology company. They proceeded to build QPID into a leader in artificial intelligence, machine learning, data science and natural language processing. QPID was among the first companies to use machine learning and statistical modeling to automate prior authorization. Doyle sold QPID to eviCore Healthcare in February 2016. eviCore is the nation's largest medical benefit management company providing service to over 120 health care payers, serving over 100 million patients. Doyle was a member of the executive committee at eviCore. In December 2017, eviCore was sold to Express Scripts, the nation's largest free standing pharmacy benefit management company, for $3.6 billion dollars. Most recently, Cigna announced its intention to buy Express Scripts for approximately $65 billion dollars.

Prior to joining QPID, Doyle was CEO and chairman of Medsphere Systems Corporation, the developer of OpenVista, an open-source enterprise electronic health record system whose basic source code originated at the Department of Veterans Affairs (VA). While president and CEO of Advantedge Health Solutions, he led the rapid expansion of a cloud based physician revenue cycle management solution for hospital-based physicians. As founder, CEO, and president of Standish Care (CareMatrix), a company he brought public, Doyle was instrumental in creating the "assisted living" category of long-term care. Additionally, he previously held senior leadership positions with two major integrated healthcare delivery systems: Voluntary Hospitals of America (VHA) and National Medical Enterprises (Tenet).

Doyle is a Fellow in the American College of Healthcare Executives (FACHE). He has served on numerous private and public company boards. He holds a BS in Biology from Tufts University with a minor in community health, and an MBA in hospital administration and finance from the University of Chicago Booth School of Business, where he was a Kaiser Fellow.

"I am very excited to work with the COTA team to continue to deliver breakthrough insights to stakeholders across the oncology continuum," said Doyle. "We are at an amazing time in history where technology can finally supplement human clinical judgement for the betterment of the patient, their family and the entire healthcare ecosystem. COTA is in a strategic position to drive value through its unique technical capability and patented Cota Nodal Address® system. This game-changing innovation was built by oncologists and data scientists – for oncology – and it's easy to see the impact that it will make to enable precision medicine at scale."

The Cota Healthcare CEO search was conducted by Ross & Company (www.RossSearch.com) the leading executive recruiting firm specializing in searches on behalf of healthcare portfolio companies sponsored by private equity and venture capital firms.

About Cota, Inc.

New York based Cota is a real-world data and analytics company that enables providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served. The company does this using the patented Cota Nodal Address® (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. Cota's breakthrough CNA system is the first and only system that precisely categorizes patient factors, their diseases, and intended therapies, enabling precision medicine at scale. For more information, please go to www.deliveringbreakthroughinsights.com.

Contact: [email protected]

SOURCE Cota, Inc.